Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Beta interferon in multiple sclerosis: pharmacological differences].

H Allain1, D Bentué-Ferrer, S Schück

  • 1Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes I.

Revue Neurologique
|June 15, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effective practices during emergency school lockdowns: shared experiences of four Australian schools.

Australian educational researcher·2022
Same author

[HIV1 group M superinfection in a HIV1 group0-infected patient].

Virologie (Montrouge, France)·2021
Same author

Acceptance of a Covid-19 vaccine is associated with ability to detect fake news and health literacy.

Journal of public health (Oxford, England)·2021
Same author

Public health impact of Infanrix hexa™ (DTPa-HBV-IPV/Hib) reimbursement: A study programme in France. Part 2: Evolution of the acceptability of infants' vaccination against hepatitis B in general and pediatric practices - the PRALINE study.

Revue d'epidemiologie et de sante publique·2016
Same author

[Prevention of venous thromboembolic events by fondaparinux 2.5 mg in general practice. ArchiMed Ville].

Journal des maladies vasculaires·2015
Same author

[Prevention of venous thromboembolic events by fondaparinux 2.5mg in patients hospitalized for an acute medical illness. ArchiMed Study].

Journal des maladies vasculaires·2015
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
Same journal

Novel variants and rare clinical presentations in MFN2-related Charcot-Marie-Tooth disease: Insights from 10 families.

Revue neurologique·2026
See all related articles

Interferons beta (IFN beta) are key treatments for relapsing remitting multiple sclerosis (RRMS). While similar, approved IFN beta therapies differ in pharmacokinetics, side effects, and molecular chemistry, impacting their clinical benefit-risk ratio.

Area of Science:

  • Immunology
  • Pharmacology
  • Neurology

Background:

  • Interferons beta (IFN beta) are established recombinant therapeutics for relapsing-remitting multiple sclerosis (RRMS).
  • Three approved IFN beta formulations exist: one IFN beta-1b (Betaferon) and two IFN beta-1a (Avonex, Rebif).
  • Despite apparent similarities, these agents exhibit significant differences.

Purpose of the Study:

  • To compare the pharmacokinetic profiles of approved Interferon beta therapies.
  • To analyze the spectrum of side effects associated with different IFN beta formulations.
  • To discuss the molecular chemistry differences and their clinical implications on the benefit-risk ratio for RRMS management.

Main Methods:

  • Review of existing literature on Interferon beta pharmacokinetics.

Related Experiment Videos

  • Comparative analysis of reported side effect profiles.
  • Examination of molecular chemistry data for approved IFN beta agents.
  • Discussion of clinical trial data and post-marketing surveillance.

    • Main Results:

    • Significant differences identified in pharmacokinetics, side effect profiles, and molecular structures among approved IFN beta therapies.
    • These variations can influence the clinical efficacy and tolerability of treatment.
    • The development and approval process for these compounds present notable challenges.

    Conclusions:

    • Understanding the distinct characteristics of each Interferon beta formulation is crucial for optimizing RRMS treatment.
    • Clinical decisions should consider individual patient factors and the specific benefit-risk profile of each agent.
    • Further analysis of basic research data may lead to improved Interferon beta therapies for multiple sclerosis.